SymBio reported sales of $25.8m (¥2.838bn) for 2019 and an operating loss of $39.1 (¥4.301bn). Sales were down from 2018 due to the previously announced quality control issue for the supply of Treakisym from Astellas. We forecast sales of $31.2m (¥3.433bn) in 2020 as the company winds down its sales to Eisai in anticipation of the launch of its own internal salesforce and marketing effort for the drug in 2021.
21 Feb 2020
SymBio Pharmaceuticals - Supply issues continue
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
SymBio Pharmaceuticals - Supply issues continue
Symbio Pharmaceuticals Limited (4582:TKS) | 0 0 0.0%
- Published:
21 Feb 2020 -
Author:
Dr Nathaniel Calloway -
Pages:
5
SymBio reported sales of $25.8m (¥2.838bn) for 2019 and an operating loss of $39.1 (¥4.301bn). Sales were down from 2018 due to the previously announced quality control issue for the supply of Treakisym from Astellas. We forecast sales of $31.2m (¥3.433bn) in 2020 as the company winds down its sales to Eisai in anticipation of the launch of its own internal salesforce and marketing effort for the drug in 2021.